BIO-key Receives Additional Nasdaq Delisting Notice for Late 10-Q, Complicating Appeal
BKYI sits 32% above its 52-week low of $3.1 on light trading volume (0.1× avg).
Summary
BIO-key received another Nasdaq non-compliance notice for a late quarterly report, further jeopardizing its appeal to remain listed on the Nasdaq Capital Market after already being suspended.
Key Events · Corporate Governance and Compliance · BKYI
-
Additional Nasdaq Non-Compliance Notice
BIO-key received a notice from Nasdaq on June 5, 2026, for failing to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. This constitutes an additional basis for delisting.
-
Impact on Delisting Appeal
This new non-compliance will be considered by the Nasdaq Hearing Panel during the company's appeal of a prior determination to suspend trading and move to OTC Markets. A hearing is scheduled for June 16, 2026.
-
Continued Listing Uncertainty
The company is taking measures to regain compliance, but there is no assurance that the Panel will grant its request for continued listing or that it will be able to maintain its Nasdaq listing.
Analysis · BKYI · Technology
BIO-key International received an additional notice from Nasdaq regarding non-compliance for failing to timely file its Q1 2026 Form 10-Q. This new violation adds to the company's existing delisting issues and will be considered by the Nasdaq Hearing Panel during the company's appeal of a prior determination to suspend trading and move to OTC Markets. This significantly complicates the company's efforts to regain and maintain its Nasdaq listing.
At the time of this filing, BKYI was trading at $4.10 on OTC in the Technology sector, with a market capitalization of approximately $4.4M. The 52-week trading range was $3.10 to $19.70. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.